Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.

@article{Richmond2012SafetyIA,
  title={Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.},
  author={Peter C. Richmond and Helen Siobhan Marshall and Michael D. Nissen and Qin Jiang and Kathrin Ute Jansen and Mar{\'i}a Garc{\'e}s-S{\'a}nchez and Frederico Martinon-Torres and Johannes Beeslaar and Leszek Szenborn and Jacek Wysocki and Joseph E Eiden and Shannon L. Harris and Thomas Russel Jones and J. Llopis P{\'e}rez},
  journal={The Lancet. Infectious diseases},
  year={2012},
  volume={12 8},
  pages={597-607}
}
BACKGROUND Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease, but a broadly protective vaccine is not currently licensed. A bivalent recombinant factor H-binding protein vaccine (recombinant lipoprotein 2086) has been developed to provide broad coverage against diverse invasive meningococcus serogroup B strains. Our aim was to test the immune response of this vaccine. METHODS This randomised, placebo-controlled trial enrolled healthy adolescents from 25… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 38 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

Similar Papers

Loading similar papers…